Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Semi-automated bladder cancer screening using machine learning: clinical validation and implementation.

Award Number: K08CA267096
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Semi-automated bladder cancer screening using machine learning: clinical validation and implementation. - Project Summary / Abstract: Bladder cancer is the 7th most common malignancy worldwide and has the highest recurrence rate of any cancer (70%).1–3 Patients with risk factors (smoking, arsenic / chemical dye exposure) and / or hematuria are routinely screened for bladder cancer via analysis of voided urine. The cellular elements of the urine are deposited to glass slides, stained, and examined by a cytopathologist for features of bladder cancer using the gold standard Paris System for Urine Cytopathology.4 However, the Paris System is subjective and the morphology of urothelial cells is highly varied, making the process difficult and prone to high interobserver variability and human errors borne of fatigue and overwork.5,6 A more quantitative, automated method of assessing urine cytopathology for bladder cancer is needed. Machine learning (ML) technologies have proven to be highly effective in image based classification in pathology, in that ML models operate reproducibly and without bias (unless the training data is biased) or fatigue. Pap smears are already routinely processed by a semi-automated ML system (BD FocalPoint), and share many common features with urine cytology specimens in that both are cancer screening tests relying on cellular and nuclear morphology and prepared by Liquid Based Preparation (LBP, e.g. ThinPrep) methods. Yet to date no system has been developed to harness ML for bladder cancer in this way, a fact I intend to change. While it is my strong belief that pathology as a discipline is poised to make the transition to a 100% digital service, there is significant inertia to overcome to replace the current analog microscope technology. We must go beyond simply providing a digital alternative by augmenting the skills of the pathologist with ML algorithms that empower them to work more efficiently, quickly and safely. Urine cytology screening for bladder cancer is an ideal use case. Thus we sought to create a prototype ML based algorithm, dubbed AutoParis, that would automate the tabulation of the Paris System. The initial prototype of AutoParis proved to be highly effective at risk stratifying urine cytology specimens by tabulating statistics related to nuclear to cytoplasmic ratio (NC ratio, a very important indicator of neoplasia) and cellular / nuclear morphological atypia.7 Deploying AutoParis as a diagnostic aid to the cytopathologist will require several additional steps. Although I was skilled enough to code the first iteration of the model, I am reaching the limits of what I can accomplish as a self-taught programmer and data scientist. In order to complete my work on AutoParis and continue to innovate in the field of digital pathology and ML, I need a more formalized education in specialized mathematics, statistics, ML theory and programming. Through this award I will pursue a curriculum of courses at Dartmouth College guided by a team of expert mentors. My mentors and collaborators were also selected for their ability to help with the testing and validation of digital decision aids, grant and manuscript prep and lab management. I will emerge from this experience with the skills I need to be a leader in the future of ML development and its adoption in clinical medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	DARTMOUTH-HITCHCOCK CLINIC	1 MEDICAL CENTER DR	LEBANON	NH	03756	GRAFTON	USA	Cancer Research Manpower	000	4	6/10/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $237,146 )
2025	2025	DARTMOUTH-HITCHCOCK CLINIC	1 MEDICAL CENTER DR	LEBANON	NH	03756	GRAFTON	USA	Cancer Research Manpower	000	4	7/30/2025	NON-COMPETING CONTINUATION	$237,146
														Subtotal = $237,146

Issue Date FY: 2024 ( Subtotal = $237,146 )
2024	2024	DARTMOUTH-HITCHCOCK CLINIC	1 MEDICAL CENTER DR	LEBANON	NH	03756	GRAFTON	USA	Cancer Research Manpower	000	3	7/25/2024	NON-COMPETING CONTINUATION	$237,146
														Subtotal = $237,146

Issue Date FY: 2023 ( Subtotal = $237,146 )
2023	2023	DARTMOUTH-HITCHCOCK CLINIC	ONE MEDICAL CENTER DR	LEBANON	NH	03756	GRAFTON	USA	Cancer Research Manpower	000	2	8/16/2023	NON-COMPETING CONTINUATION	$237,146
														Subtotal = $237,146

Issue Date FY: 2022 ( Subtotal = $237,146 )
2022	2022	DARTMOUTH-HITCHCOCK CLINIC	ONE MEDICAL CENTER DR	LEBANON	NH	03756	GRAFTON	USA	Cancer Research Manpower	000	1	9/1/2022	NEW	$237,146
														Subtotal = $237,146

Grand Total All Awards = $948,584

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Semi-automated bladder cancer screening using machine learning: clinical validation and implementation.

Award Number: K08CA267096

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer